Identifying weaknesses in a type of cancer linked to genetic mutations.
Official title: Genome-wide synthetic lethal screening for vulnerabilities in a cell model of succinate dehydrogenase-loss paraganglioma
Funded at Mayo Clinic Rochester · NIH-10750986 · Data updated 2026-11-12
This study is looking at a type of inherited cancer called familial paraganglioma to find out how certain genetic weaknesses in cancer cells can help us develop new treatments that specifically target those weaknesses.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | December 8, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $176,539 |
| NIH project number | 5R21CA266999-02 |
| Project ID | NIH-10750986 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with familial paraganglioma or those with genetic predispositions to this type of cancer.
✕Less likely to help
Patients without succinate dehydrogenase-loss paraganglioma or those with other unrelated cancers may not benefit from this research.
What this research studies
This research investigates familial paraganglioma, a neuroendocrine cancer caused by inherited mutations that affect a key enzyme in energy production. By using a genome-wide synthetic lethal screening approach, the study aims to uncover specific genetic vulnerabilities in cancer cells that have lost succinate dehydrogenase function. This could lead to the identification of targeted therapies that exploit these weaknesses. The research employs advanced techniques such as CRISPR to systematically analyze gene interactions and their effects on cancer cell survival.
Why it matters
Potential benefit: If successful, this research could lead to new targeted treatments for patients with succinate dehydrogenase-loss paraganglioma.
How similar studies have gone: Previous research has successfully utilized similar genome-wide screening approaches to identify vulnerabilities in other cancer types, suggesting potential for success in this study.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Maher, Louis James — Mayo Clinic Rochester
- Study coordinator: Maher, Louis James
Related research
Other NIH-funded projects on the same topics.
-
Understanding how genetic background affects rare tumors and their treatment responses
This study is looking at how your genetic background might affect the way rare tumors called pheochromocytomas and paragangliomas behave and respond to treatment, especially for patients from underrepresented racial and ethnic groups, to help find better ways to detect and treat these tumors.
-
Understanding genetic factors in hereditary paraganglioma and pheochromocytoma syndrome
This study is looking at how certain genes might affect the chances of developing adrenal tumors called paragangliomas and pheochromocytomas, so if you or someone you know is at risk, this research could help improve testing and treatment options for you.
-
NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma
This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.
-
Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents
This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.
-
Registry for Rare Diseases
This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.
-
Understanding genetic causes of neuroendocrine tumors in Mexican patients
This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.